Rate or Rhythm Control in CRT: the RHYTHMIC Study

Last updated: January 23, 2026
Sponsor: Guy's and St Thomas' NHS Foundation Trust
Overall Status: Active - Recruiting

Phase

N/A

Condition

Arrhythmia

Congestive Heart Failure

Chest Pain

Treatment

AV node ablation

AF catheter ablation

Clinical Study ID

NCT04664686
265388
  • Ages 18-85
  • All Genders

Study Summary

70 patients with heart failure, AF and CRT with BiV<95% will be randomised to either AF ablation or AV node ablation. Evaluation at 6 months with echocardiography and clinical assessment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Ability to provide informed consent to participate and willing to comply with theclinical investigation plan and follow-up schedule.

  • QRS duration >120ms on surface ECG, severe left ventricular systolic impairment (EF≤35%) and clinical symptoms of heart failure despite optimum medical therapy (NYHA class II-IV) at time of CRT implant or upgrade

  • Successful CRT implant or upgrade including atrial lead

  • Biventricular pacing percentage <95% secondary to atrial fibrillation at least 3months post implant or upgrade

  • Clinically indicated for AV node ablation

Exclusion

Exclusion Criteria:

  • Life expectancy <1 year

  • Presence of atrial or ventricular thrombus

  • Permanent atrial fibrillation

  • Mechanical aortic valve replacement

  • Severe peripheral vascular disease

  • Female participants who are pregnant, lactating or planning pregnancy during thecourse of the study.

  • Participation in other studies with active treatment / investigational arm

Study Design

Total Participants: 70
Treatment Group(s): 2
Primary Treatment: AV node ablation
Phase:
Study Start date:
October 19, 2021
Estimated Completion Date:
September 30, 2027

Study Description

70 patients with heart failure, AF and CRT with BiV<95% will be recruited from outpatient clinic, pacing clinic or inpatient wards. Patients will be consented and will undergo baseline investigation with a transthoracic 2D echocardiogram, ECG, blood tests, cardiac CT with perfusion imaging, 6 minute walk test (6MWT), cardio-pulmonary exercise test (CPET) and Minnesota Living with Heart Failure Questionnaire. Patients who are successfully screened will be randomized 1:1 to receive AF catheter ablation rhythm control or AV-node ablation rate control.

Ablation Procedure:

Patients will receive either AF catheter ablation or AV-node ablation during the procedure. Patients randomised to AF catheter ablation will receive isolation of all four pulmonary veins and additional lesions, considered indicated by the operator. The procedure will be classified as successful if all four veins are isolated and the patient is in sinus rhythm. Patients may undergo DC-cardioversion under sedation if they remain in atrial fibrillation. AV-node ablation will be performed in line with current standard of care. Patients will also undergo additional research investigations at the time of ablation as follows:

Acute Haemodynamic Study:

All patients will also undergo an acute haemodynamic study with pressure wire assessment of both the right ventricle and the left ventricle at the start and end of the procedure. This involves inserting pressure wires into the RV via a vein in the groin and into the LV via an artery in the wrist or the groin. This will provide novel information on how AF catheter ablation and AV-node ablation affect cardiac contractility.

Invasive Electroanatomical Mapping (Optional):

This is an optional additional procedure that patients may opt into at the time of recruitment. This is performed during the ablation procedure with mapping catheters and software which are CE marked and already in clinical use. Mapping of all four cardiac chambers will be performed. This will be achieved via a vein and an artery in the groin. This will provide novel information on how AF catheter ablation and AV-node ablation affect electrical activation of the atria and ventricles.

Follow-up:

Patients will undergo a 2D transthoracic echocardiogram and ECG 1 week post ablation. Patients will then be followed up at 6 months with 2D transthoracic echocardiogram, ECG, clinical review, CPET, 6MWT, Minnesota Living with Heart Failure Questionnaire and pacing check.

Patients in the AF catheter ablation group who have a recurrence of AF after a 3 month blanking period will be permitted a re-do procedure. The follow-up investigations will take place 6 months after the re-do procedure. If a patient has recurrence of AF after a second ablation procedure and it is felt a third procedure is indicated, this will be performed after the six month follow-up period has ended and the patient is no longer in the study. They will be included in the intention-to-treat analysis.

Connect with a study center

  • Guys and St Thomas' NHS Foundation Trust

    London, SE1 7EH
    United Kingdom

    Site Not Available

  • Guys and St Thomas' NHS Foundation Trust

    London 2643743, SE1 7EH
    United Kingdom

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.